Loading...
•
Dec 31, 2023
Akebia Q4 2023 Earnings Report
Estimated Revenue:$54.3M
+16.9% YoY
Estimated EPS:-$0.039
+78.9% YoY
Key Takeaways
Akebia Therapeutics reported a net income of $0.6 million for Q4 2023, compared to a net loss of $6.1 million for Q4 2022. Total revenues for the quarter were $56.2 million, slightly up from $55.8 million in the same period last year. The company is preparing for the potential launch of vadadustat, pending FDA approval.
Akebia awaits potential vadadustat U.S. approval with a PDUFA date of March 27, 2024.
The company strengthened its balance sheet with a $55.0 million term loan and $26.0 million from ATM proceeds.
Q4 2023 Auryxia net product revenues reached $53.2 million.
New pipeline programs were introduced in acute care settings, including AKB-9090 and AKB-10108.
Revenue by Segment
Forward Guidance
Akebia expects Auryxia net product revenue growth in 2024, with a quarterly revenue cadence similar to 2023. The company believes its financial strategies will support business operations for at least two years if vadadustat is approved and will continue to carefully manage expenses while investing appropriately for a successful potential launch of vadadustat.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...